DLH Holdings Corp. — FY2023 Form 10-K
Reporting period: Fiscal year ended September 30, 2023. This is an annual report, not a standalone fiscal fourth-quarter results filing; the filing identifies a fourth-quarter impairment but does not provide a clear standalone Q4 income statement.
Business context
DLH provides technology-enabled health, science research, cybersecurity, and systems engineering services primarily to U.S. federal agencies. In December 2022, it acquired Grove Resource Solutions, LLC (GRSi) for approximately $188.0 million, expanding its federal research, engineering, and military health capabilities. GRSi contributed $107.0 million in revenue and $4.4 million in operating income after acquisition.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $375.9 million | $395.2 million |
| Operating income / margin | $17.1 million / 4.5% | $33.3 million / 8.4% |
| Interest expense | $16.3 million | $2.2 million |
| Net income / diluted EPS | $1.5 million / $0.10 | $23.3 million / $1.64 |
| Operating cash flow | $31.0 million | $1.2 million |
| Cash at year-end | $0.2 million | $0.2 million |
Revenue declined 4.9%, primarily because two FEMA COVID-response task orders that generated $125.8 million in FY2022 ended. Excluding those task orders, company-defined adjusted revenue rose to $375.9 million from $269.4 million. Management-reported adjusted EBITDA was $42.1 million versus $29.1 million, and adjusted EBITDA margin on adjusted revenue was 11.2% versus 10.8%. These are non-GAAP measures and exclude specified items, including FEMA task-order contribution in FY2022.
FY2023 operating cash flow increased largely due to lower accounts receivable. Investing used $181.2 million, predominantly for the GRSi acquisition; financing provided $150.2 million, primarily from acquisition-related borrowing. At September 30, gross debt obligations were approximately $179.4 million: a $169.8 million term loan and $9.5 million revolver balance. The company reported $32.0 million of unused revolver capacity, subject to borrowing conditions. Debt is secured by substantially all company assets; management expects operating cash flow to support operations for 12 months and to continue reducing debt.
The company’s $70 million revolving facility and term loan mature in December 2027 and bear interest at SOFR plus 4.1%. Interest-rate swaps covered $112.2 million of notional debt at year-end. Management estimated a 1 percentage-point SOFR increase would add approximately $0.7 million of annual interest expense. The company reported compliance with debt covenants at September 30, 2023.
Material changes and unusual items
- Customer mix shifted substantially: HHS revenue increased to $161.3 million from $102.2 million, DoD to $70.3 million from $33.6 million, while DHS fell to $0.9 million from $126.6 million following the FEMA task-order completions. VA revenue was $138.9 million, up from $126.1 million.
- Interest expense rose by $14.1 million, primarily from debt incurred to finance GRSi. Depreciation and amortization increased to $15.6 million from $7.7 million, largely reflecting the acquisition and acquired intangible assets.
- DLH recorded a $7.7 million impairment loss in FY2023’s fourth quarter after consolidating underused leased office space and reducing the carrying value of lease right-of-use assets.
- Backlog increased to approximately $704.8 million from $482.5 million; funded backlog was $169.9 million versus $98.9 million. Backlog includes options and estimates and is not assured revenue.
Outlook, risks, and contingencies
Management cited continued federal priorities in public health, veterans’ services, military health, and cybersecurity, and said it did not expect budget negotiations to materially affect its current business base. It also warned that continuing resolutions can delay new program starts, contract awards, and payments. The filing provides no quantified company financial guidance.
- Federal agencies account for approximately 99% of revenue. HHS, VA, and DoD together represented 98.6% of FY2023 revenue.
- VA pharmacy and logistics contracts supporting the CMOP program were operating under bridge arrangements through December 31, 2023. New solicitations were set aside for SDVOSB prime contractors; DLH said it might continue as a subcontractor through partners or compete if solicitations became unrestricted.
- Key risks include contract recompetes, government set-asides, appropriations delays or shutdown, termination rights, competitive bidding and protests, employee retention, inflation and labor costs, cybersecurity, and the ability to integrate GRSi and service acquisition-related debt.
- Management reported no pending or threatened litigation it believed reasonably likely to have a material adverse effect. The independent auditor gave unqualified opinions on the financial statements and internal controls; identified critical audit matters were workers’ compensation claims liabilities and the GRSi business combination.
Important facts for investors to verify
- Outcomes and timing of VA CMOP recompetes, bridge extensions, and any subcontracting arrangements.
- Conversion of backlog—particularly the $169.9 million funded portion—into revenue and cash, and renewal of major HHS and DoD work.
- Debt reduction, covenant headroom, refinancing exposure, and sensitivity to floating interest rates.
- Whether GRSi delivers expected growth and integration benefits, and whether acquired goodwill and intangible assets remain supportable.
- Drivers of the sharp GAAP earnings decline and the assumptions underlying company-defined adjusted results.